Harrow Health Acquires Melt Pharmaceuticals for Expansion

Harrow Health ( (HROW) ) has issued an update.

On September 26, 2025, Harrow announced its agreement to acquire Melt Pharmaceuticals, a company specializing in non-opioid, non-IV sedation therapies. This acquisition, subject to customary closing conditions, aims to strengthen Harrow’s portfolio and market presence by integrating Melt’s innovative MELT-300 product, which has shown clinical superiority in sedation without the need for intravenous administration. The acquisition is expected to diversify Harrow’s business, enhance operational synergies, and expand market opportunities, particularly in the U.S. procedural sedation market.

The most recent analyst rating on (HROW) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.

Spark’s Take on HROW Stock

According to Spark, TipRanks’ AI Analyst, HROW is a Neutral.

Harrow Health’s overall stock score is driven by strong earnings call results and positive technical indicators, indicating growth potential. However, significant financial performance challenges and valuation concerns weigh heavily on the score. Addressing cash flow issues and improving profitability are crucial for enhancing financial stability.

To see Spark’s full report on HROW stock, click here.

More about Harrow Health

Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address various eye conditions such as dry eye disease, cataracts, and glaucoma. The company is committed to delivering safe, effective, and affordable medications to enhance patient compliance and improve clinical outcomes.

Average Trading Volume: 568,799

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.77B

Learn more about HROW stock on TipRanks’ Stock Analysis page.